Valuation
- Market cap
- 82,004,000
- Revenue TTM
- $3,570,000
- Net income TTM
- $-7,800,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -218.49%
- Debt to equity
- 0.00
Trading
- Volume
- 1,127,000
- Avg volume
- 136,828
- Day's range
- $6.80 – $7.84
- Shares out
- 12,558,000
- Stochastic %K
- 95%
- Beta
- 1.38
- Analysts
- Sell
- Price target
- $13.00
Company profile
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and as...
Show more
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 812 689 0791
- Website
- https://neuraxis.com
- Address
- 11611 North Meridian St, Suite 330, Carmel, United States
Latest news
No headlines yet.
